Charles River announces stem cells collaboration with Pluristyx

Charles River Laboratories International announced that it has entered into an agreement with Pluristyx . The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem ES cells and induced pluripotent stem cells iPSCs as research tools to support development of new therapeutics. Pluristyx offers a unique product and technology platform in the stem cell biology field for development of new therapies while reducing timelines and downstream costs. Through the agreement, Charles River will distribute Pluristyx’s wild-type and genetically engineered iPSCs as well as their comprehensive portfolio of normal and disease state ES cell lines. All of Pluristyx’s pluripotent cell lines are produced under full donor consent and the ES cell lines are registered and approved by the U.S. National Institutes of Health making them eligible for use in NIH-funded research. Pluristyx’s iPSC panCELLa platform includes the proprietary FailSafe safety-switch technology enabling the development of safer, next-generation cell therapies. Under the terms of the agreement, Charles River will distribute a broad catalog of Pluristyx’s ES and iPS cell lines for research use and will exclusively offer specific pluripotent stem cell lines derived under Good Tissue Practice to support a path to the clinic. The addition of Pluristyx’s offerings complements Charles River’s expansive portfolio of high-quality human cellular materials.